SABCS 2022 Meeting News Welcome Edition - 6

6
THURSDAY, DECEMBER 8
SCHEDULE-AT-A-GLANCE
*As of November 18, 2022 | **All times are CENTRAL Time
7:00 am - 8:15 am CT
POSTER SESSION 4
Hall 1
SPOTLIGHT POSTER
DISCUSSION
SESSION #10:
Endocrine Therapy and
Resistance
Stars at Night Ballroom 3&4
SPOTLIGHT POSTER
DISCUSSION
SESSION #11:
Improving Outcome for
TNBC: New Directions in
Immunotherapy
Stars at Night Ballroom 1&2
SPOTLIGHT POSTER
DISCUSSION
SESSION #12:
Obesity and Breast Cancer
Hemisfair Ballroom 1&2
8:30 am - 11:00 am CT
GENERAL SESSION #3
Hall 3
10:00 am - 5:00 pm CT
EXHIBITS
Hall 2
11:00 am - 12:00 pm CT
Debate: Are All of CDK4/6
Inhibitors the Same or Different?
Hall 3
12:00 pm - 12:30 pm CT
Plenary Lecture: Premenopausal
ER+ Breast Cancer: Past,
Present, and Future
Prudence Francis, MD
Hall 3
12:30 pm - 1:00 pm CT
Brinker Award for Scientific
Distinction in Basic Science
Lecture
Geoffrey M. Wahl, PhD
Hall 3
1:00 pm - 2:00 pm CT
Molecular Tumor Board
Stars at Night Ballroom 1&2
Forum: Modifying Tumor Response:
Microbiome, Diet, and Fasting
Stars at Night Ballroom 3&4
2:00 pm - 3:00 pm CT
Translational Controversies
Stars at Night Ballroom 1&2
Forum: Demystifying CDKs in
Breast Cancer: Beyond CDK4/6
Stars at Night Ballroom 3&4
GENERAL SESSION #3
ABSTRACT PRESENTATIONS
Thursday, December 8 | 8:30 am - 11:00 am CT | Hall 3
8:30 am - 8:45 am CT
GS3-01: EMERALD phase 3
trial of elacestrant versus
standard of care endocrine
therapy in patients with ER+/
HER2- metastatic breast cancer:
Updated results by duration of
prior CDK4/6i in metastatic
setting
8:45 am - 9:00 am CT
GS3-02: Camizestrant, a
next generation oral SERD vs
fulvestrant in post-menopausal
women with advanced ER-
positive HER2-negative
breast cancer: Results of the
randomized, multi-dose Phase 2
SERENA-2 trial
9:00 am - 9:15 am CT
GS3-03: ARV-471, a PROTAC®
estrogen receptor (ER) degrader
in advanced ER-positive/human
epidermal growth factor receptor
2 (HER2)-negative breast cancer:
phase 2 expansion (VERITAC) of
a phase 1/2 study
9:15 am - 9:30 am CT
GS3-04: Capivasertib and
fulvestrant for patients with
aromatase inhibitor-resistant
hormone receptor-positive/
human epidermal growth factor
receptor 2-negative advanced
breast cancer: results from the
Phase III CAPItello-291 trial
9:30 am - 9:45 am CT
Discussant for GS3-01, GS3-02,
GS3-03 and GS3-04
9:45 am - 10:00 am CT
GS3-06: Palbociclib After
CDK4/6i and Endocrine Therapy
(PACE): A Randomized Phase II
Study of Fulvestrant, Palbociclib,
and Avelumab for Endocrine Pre-
treated ER+/HER2- Metastatic
Breast Cancer
10:00 am - 10:15 am CT
GS3-07: Clonal evolution and
mechanisms of acquired resistance
to CDK4/6 inhibitors in ER-wild
type and ER-mutant breast cancer
10:15 am - 10:30 am CT
Discussant for GS3-06 and
GS3-07
10:30 am - 10:45 am CT
GS3-09: Circulating Tumor Cells-
driven choice of first line therapy
for ER+ HER2- metastatic breast
cancer: overall survival analysis of
the randomized STIC CTC trial
10:45 am - 11:00 am CT
Discussant for GS3-09
SABCS Meeting News is published by TriStar Event Media, LLC, as a service to attendees and followers of the San Antonio Breast Cancer Symposium.
www.SABCS.org | ©2022 All rights reserved.
TriStar Event Media, Inc. | 7285 W. 132nd St., Suite 300 | Overland Park, KS 66213 | www.tristareventmedia.com
WELCOME EDITION | SABCSMEETINGNEWS . ORG
3:00 pm - 5:00 pm CT
EDUCATIONAL SESSION BLOCK #3
Management of Hereditary Risk:
Moderate-Risk Genes and New
Approaches
Hemisfair Ballroom 1&2
Challenging Types of Breast Cancer
Stars at Night Ballroom 1&2
What ctDNA Can Tell Us
Stars at Night Ballroom 3&4
5:00 pm - 6:15 pm CT
POSTER SESSION #5
Hall 1
SPOTLIGHT POSTER
DISCUSSION SESSION #13
Therapeutic Approaches for
HR+/HER2- Breast Cancer
Stars at Night Ballroom 1&2
SPOTLIGHT POSTER
DISCUSSION SESSION #14
Breast Cancer Risk Modeling
Stars at Night Ballroom 3&4
SPOTLIGHT POSTER
DISCUSSION SESSION #15:
Local Regional/Management of
the Axilla
Hemisfair Ballroom 1&2
7:00 pm - 10:00 pm CT
OPEN SATELLITE EVENTS
Marriott Rivercenter
PRESENTER
PROFILE:
Guido Kroemer, MD,
PhD, PU-PH
Professor at the Faculty of
Medicine of the University
of Paris Descartes
Director of the research
team " Metabolism, Cancer
and Immunity " of the
French Medical Research
Council (INSERM)
FORUM:
Modifying Tumor Response:
Microbiome, Diet, and Fasting
Thursday, 1:00 pm - 2:00 pm CT
Stars at Night Ballroom 3&4
PRESENTATION:
Fasting and Microbiotic
Q: What is your presentation about?
A: One of the most salient risk factors of breast
cancer is overnutrition resulting in obesity
and its comorbidities: metabolic syndrome,
diabetes, steatohepatitis, cardiovascular and
malignant diseases. I will talk about the benefits
of fasting and caloric restriction mimetics
(agents that mimic the effects of caloric
restriction) on preventing breast cancer in
preclinical models. These benefits are mediated
by an improvement of immunosurveillance,
which plays a major role in the avoidance of
human breast cancer as well.
Q: What makes this topic important
in 2022?
A: There is increasing awareness of the
importance of immunosurveillance, i.e., the
capacity of the immune system to eliminate
(pre)malignant cells and hence prevent
oncogenesis and delay tumor progression.
Immunotherapy is starting to become an
option for breast cancer patients. It should
be noted that therapies classically thought
to directly act on cancer cells including
chemotherapies, radiotherapies and targeted
therapies (and even estrogen receptor
antagonists) also mediate a large part of their
efficacy by enhancing immunosurveillance.
Q: How/why did you become
involved with this area of breast
cancer research or care?
A: As a cell biologist, immunologist, and
physician, I am particularly interested in frequent,
socioeconomically impactful diseases. Among
the different types of malignancy, breast cancer
constitutes the paradigm of a highly prevalent
neoplasia that should be targeted by prophylactic
measures, early detection strategies, as well
as sophisticated, highly stratified personalized
treatments. Years ago, we discovered the cardinal
importance of the chemotherapy-induced
immune response for treatment outcome. Based
on this paradigm shift, we focused our attention
on the natural and therapy-induced immune
control of breast cancer. 
http://www.SABCS.org http://www.tristareventmedia.com
SABCS 2022 Meeting News Welcome Edition

Table of Contents for the Digital Edition of SABCS 2022 Meeting News Welcome Edition
